Previous 10 | Next 10 |
2024-01-10 16:25:49 ET More on Praxis Precision Medicines Seeking Alpha’s Quant Rating on Praxis Precision Medicines Historical earnings data for Praxis Precision Medicines Financial information for Praxis Precision Medicines For further details see: ...
2024-01-08 12:31:25 ET Gainers: Harpoon Therapeutics ( HARP ) +112% . Ambrx Biopharma ( AMAM ) +101% . Nkarta ( NKTX ) +47% . Mountain Crest Acquisition Corp IV ( MCAF ) +45% . Spectaire Holdings ( SPEC ) +43% . Neximmune ( ...
Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds expectations; topline results expected in 1Q 2024 after completion of 45 mg cohort Enrollment for both ulixacaltamide Phase 3 Studies in the Essential3...
Collaboration leverages Tenacia’s expertise in central nervous system drug development and commercialization and will address a significant unmet patient need Praxis to receive upfront proceeds of $15 million and is eligible to receive up to $264 million in milestone payments as ...
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imba...
BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imba...
BOSTON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imba...
Praxis Precision Medicines Inc. (PRAX) is expected to report $-0.35 for Q3 2023
2023-11-07 08:24:33 ET More on Praxis Precision Medicines Praxis, Ionis stocks dip in wake of Praxis drug updates Praxis Precision Meds up 9% on new Truist buy rating Seeking Alpha’s Quant Rating on Praxis Precision Medicines For further details see: ...
Essential3 study initiated, with over 600 patients engaged in pre-recruitment observational study Elsunersen EMBRAVE study final dose completed, Praxis seeking FDA advice on advancing development Cash of $101.1 million as of September 30, 2023 supports runway into ...
News, Short Squeeze, Breakout and More Instantly...
Praxis Precision Medicines Inc. Company Name:
PRAX Stock Symbol:
NASDAQ Market:
Praxis Precision Medicines Inc. Website:
2024-05-20 14:30:05 ET Piper Sandler analyst issues OVERWEIGHT recommendation for PRAX on May 20, 2024 12:01PM ET. The previous analyst recommendation was Overweight. PRAX was trading at $44.93 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-16 16:30:03 ET Jefferies analyst issues BUY recommendation for PRAX on May 16, 2024 02:01PM ET. The previous analyst recommendation was Buy. PRAX was trading at $45.32 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...